NASD · Healthcare · Biotechnology · USA
Mirum Pharmaceuticals Inc is a mid cap company (market value between $2 billion and $10 billion) in the Biotechnology industry.
Mirum Pharmaceuticals is a biopharmaceutical company treating rare diseases. It markets three approved medicines for cholestatic conditions and bile acid disorders in the United States, Canada and Europe. The company also develops clinical-stage candidates for cholestatic liver diseases, hepatitis delta virus infection, and fragile X syndrome.
From its FY2025 annual report (Form 10-K)
Intrinsic value, DCF valuation, financial health and value investing analysis for the Mirum Pharmaceuticals Inc stock.
Overvalued: intrinsic value $62.86 per share, market price $82.24, margin of safety -30.8% (as of 2026-10-19).
A 7.1x revenue multiple, discounted for its losses, values the shares at $62.86; the price of $82.24 is 31% above that value.
17 more funds hold it; the full list is part of the paid plan.
41 more in this industry show a wider margin of safety.
MIRM is overvalued (as of the 2026-10-19 close). A 7.1x revenue multiple, discounted for its losses, values the shares at $62.86; the price of $82.24 is 31% above that value.
$62.86 per share (as of the 2026-10-19 close), against a market price of $82.24. That is a margin of safety of -30.8%. The value is the average of the valuation methods that apply to this company, recomputed every night after the US close.